Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2022

Open Access 01.12.2022 | Research

Development and validation of a predictive model for adverse left ventricular remodeling in NSTEMI patients after primary percutaneous coronary intervention

verfasst von: Lili Wang, Tao Liu, Chaofan Wang, Haochen Xuan, Xianzhi Xu, Jie Yin, Xiaoqun Li, Junhong Chen, Dongye Li, Tongda Xu

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2022

Abstract

Introduction

To develop and validate clinical evaluators that predict adverse left ventricular remodeling (ALVR) in non-ST-elevation myocardial infarction (NSTEMI) patients after primary percutaneous coronary intervention (PCI).

Methods

The retrospective study analyzed the clinical data of 507 NSTEMI patients who were treated with primary PCI from the Affiliated Hospital of Xuzhou Medical University and the Second Affiliated Hospital of Xuzhou Medical University, between January 1, 2019 and September 31, 2021. The training cohort consisted of patients admitted before June 2020 (n = 287), and the remaining patients (n = 220) were assigned to an external validation cohort. The endpoint event was the occurrence of ALVR, which was described as an increase ≥ 20% in left ventricular end-diastolic volume (LVEDV) at 3–4 months follow-up CMR compared with baseline measurements. The occurrence probability of ALVR stemmed from the final model, which embodied independent predictors recommended by logistic regression analysis. The area under the receiver operating characteristic curve (AUC), Calibration plot, Hosmer–Lemeshow method, and decision curve analysis (DCA) were applied to quantify the performance.

Results

Independent predictors for ALVR included age (odds ratio (OR): 1.040; 95% confidence interval (CI): 1.009–1.073), the level of neutrophil to lymphocyte ratio (OR: 4.492; 95% CI: 1.906–10.582), the cardiac microvascular obstruction (OR: 3.416; 95% CI: 1.170–9.970), peak global longitudinal strain (OR: 1.131; 95% CI: 1.026–1.246), infarct size (OR: 1.082; 95% CI: 1.042–1.125) and left ventricular ejection fraction (OR: 0.925; 95% CI: 0.872–0.980), which were screened by regression analysis then merged into the nomogram model. Both internal validation (AUC: 0.805) and external validation (AUC: 0.867) revealed that the prediction model was capable of good discrimination. Calibration plot and Hosmer–Lemeshow method showed high consistency between the probabilities predicted by the nomogram (P = 0.514) and the validation set (P = 0.762) and the probabilities of actual occurrence. DCA corroborated the clinical utility of the nomogram.

Conclusions

In this study, the proposed nomogram model enabled individualized prediction of ALVR in NSTEMI patients after reperfusion and conduced to guide clinical therapeutic schedules.
Hinweise
Lili Wang and Tao Liu are co-first authors

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ALVR
Adverse left ventricular remodeling
AUC
Area under the receiver operating characteristics curve
BMI
Body mass index
CAD
Coronary artery disease
CHOL
Total cholesterol
CI
Confdence interval
CKMB
Creatine kinase isoenzyme-MB
CMVO
The cardiac microvascular obstruction
CO
Cardiac output
CREA
Serum creatinine
cTnI
Cardiac troponin I
DBP
Diastolic blood pressure
DCA
Decision curve analysis
D2B
Door-to-balloon time
GCS
Peak global circumferential
GLS
Peak global longitudinal strain
GRS
Peak global radial strain
HbA1c
Hemoglobin A1c
HDL-C
High-density lipoprotein-cholesterol
HR
Heart rate
HGB
Hemoglobin
HR
Heart rate
hs-CRP
High-sensitivity C-reactive protein
hsTnT
High-sensitivity troponin T
IMH
Intramyocardial hemorrhage
IS
Infarct size
LAD
Left anterior descending
LCX
Left circumflex branch
LDH
Lactate dehydrogenase
LDL-C
Low density lipoprotein-cholesterol
Lpa
Lipoprotein a
LVEDV
Left ventricular end diastolic volume
LVEF
Left ventricular ejection fraction
LVESV
Left ventricular end systolic volume
NLR
Neutrophil to lymphocyte ratio
non-culprit CTO
Non-culprit chronic total occlusion
NSTEMI
Non-ST elevation myocardial infarction
NT-proBNP
N-terminal pro-brain natriuretic peptide
OR
Odds ratio
PCI
Percutaneous coronary intervention
PLT
Platelets
pre-AP
Pre-infarction angina
RCA
Right coronary artery
SBP
Systolic blood pressure
SBT
Symptom onset-to-balloon time
TG
Triglycerides
UA
Serum uric acid
WBC
White blood cell

Introduction

More than 7 million patients with new-onset myocardial infarction on a global scale each year, which holds a serious negative impact on human health [1]. Percutaneous coronary intervention (PCI) therapy could open infarct-related vessels in time and reduce short-term mortality significantly [2]. However, numerous patients with myocardial infarction are gradually subjected to adverse left ventricular remodeling (ALVR) after successful reperfusion, afterwards leading to poor outcome events, such as heart failure and even death [3]. Recent studies have demonstrated that patients with non-ST-elevation myocardial infarction (NSTEMI) have a significantly higher risk of adverse events such as late death during follow-up compared with STEMI patients [4, 5]. Moreover, NSTEMI accounts for more than 70% of all myocardial infarction nowadays, and this proportion has been on the rise in recent years [6]. Therefore, early prediction of ALVR is considerable for the interference of therapeutic schedule and the improvement of prognosis in patients with NSTEMI after PCI.
ALVR is a complex process that brings about a range of irreversible changes in the structure and function of the cardiovascular system in response to some physiological and pathological stimuli [7]. At present, the clinical diagnosis of ALVR is mainly based on morphological testing, including the changes in cavity diameter, geometry and scar area after myocardial infarction [8]. In imaging, ALVR is usually characterized as an increase of ≥ 20% in the end-diastolic volume compared with baseline measurement [9], and the conventional detection methods are composed of echocardiography, radionuclidic imaging, and cardiac magnetic resonance (CMR). The imaging quality and measurement accuracy of echocardiography depend on some factors such as acoustic window conditions and the experience of the operator, leading to more subjective results [7]. Radionuclide imaging not only requires the use of radiopharmaceuticals, but also is limited by spatial resolution [10]. CMR has been recognized as the “gold standard” for the non-invasive estimation of cardiac morphology and function owing to its distinguished resolution, accuracy, reproducibility, and non-radioactive feature [11]. Meanwhile, it could provide a “one-stop” examination of the anatomical structure, motor function, myocardial perfusion, and tissue characteristics of the heart, so the correlative indices of CMR were applied to evaluate ALVR in the study. A quite number of projects have been conducted to explore predictors of ALVR, and the results contained circulating biomarkers, angiography, imaging parameters, etc. [1217]. Note that previous studies on ALVR were mostly confined to ST-elevation myocardial infarction, while NSTEMI were few involved. Furthermore, most of these researches have been concentrated on the analysis of single independent risk factors, and a comprehensive predictive scoring system integrating the predictors has not been established to date.
Nomogram, a graphical form of the clinical prediction model, can calculate the probability of an event quantitatively [18]. As a result of its intuitiveness and accuracy, the nomogram has been broadly applied in medical diagnosis, treatment strategies, and prognosis management [19]. The study aimed at building a risk prediction nomogram based on clinical data of Chinese patients, which can early screen patients at high risk for ALVR events, for timely intervention and treatment to improve the long-term prognosis of patients.

Material and methods

Study population and design

This study was conducted by the Declaration of Helsinki and was approved by the Medical Research Ethics Committee of the Affiliated Hospital of Xuzhou Medical University. All clinical information involved for retrospective analysis were available from the Affiliated Hospital of Xuzhou Medical University and the Second Affiliated Hospital of Xuzhou Medical University. 742 consecutive patients with first-onset NSTEMI hospitalized between January 1, 2019 and September 31, 2021 were initially included. Patients who conformed to all the following conditions were collected: (1) Patients were diagnosed with NSTEMI by relevant guidelines and received primary PCI successfully (TIMI grade ≥ 2 after PCI) within 24 h; (2) Patients received cardiac magnetic resonance (CMR) within 7 days after revascularization. Exclusive criteria: (1) Medical history of myocardial infarction or coronary artery bypass grafting; (2) Patients with one of the following complications: severe liver or kidney disfunction, malignant tumour, acute infection, severe haematological disorder, autoimmune disease, congenital heart disease, malignant arrhythmia, rheumatic heart disease, Killip class III or IV; (3) Patients lost to follow-up.
Ultimately, 507 patients were included in this study. 287 patients admitted before June 1, 2020 were assigned to the training cohort, and 220 patients admitted after May 31, 2020 were splitted into the validating cohort. The nomogram was established and validated through the training and validation groups, respectively. Patient enrollment and study design were shown in Fig. 1.

Treatment strategies during hospitalization

All patients were administered the loading dose of 300 mg aspirin, 600 mg clopidogrel or 180 mg ticagrelor before the procedure, exclusive of those who had received dual antiplatelet therapy (DAPT) one week before the operation. Therapeutic schedule: all patients underwent coronary angiography and then underwent PCI or drug conservative treatment according to the characteristics of coronary lesions and the attitudes of patients’s families. The selection of interventional equipment and adjuvant drugs (nitroprusside, atropine, tirofiban, etc.) were determined by operators on the basis of the specific situation of each patient. After the operation, all patients were treated with DAPT in accordance with the related guidelines, β-blockers, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, statins, nitrates, aldosterone antagonists and other drugs, as appropriate.

CMR imaging protocol

CMR imaging was performed with a 3.0-T MRI Scanner (Ingenia 3.0 T, Philips Healthcare, The Netherlands) within 7 days and 3–4 months after primary PCI, equipped with a 5-unit cardiac coil, electrocardiographically-gated technique, and a dual-channel high pressure injector. Patients remained in supine position, and images were captured while the patient was holding his breath at the end of a calm exhalation. Cine Imaging: free steady-state fast gradient echo (BTFE) sequence, continuous scanning from apex of the LV to base and three long-axis planes (2, 3, and 4 chambers) to assess cardiac function and volume. Black Blood Imaging: T2-weighted short-tau inversion recovery (T2-STIR) sequences, scanned covers the entire left ventricular short-axis to evaluate compositional changes in myocardial tissue. Perfusion imaging: Dynamic SENSE-TFE sequences, scanning left ventricular short-axis position while Gd-DTPA (0.15 mmol/kg, 3 mL/s) was injected intravenously. Late gadolinium enhancement (LGE) images were captured 15–20 min after contrast injection through the phase-sensitive inversion recovery (PSIR) sequence. The scanning parameters: echo time 1.4 ms, repetition time 2.30 ms, section thickness 8 mm, the field of view 350 * 350 mm.

CMR image post-processing

CMR cine images post-processing were performed with CVI software (version 5.13.9, Circle Cardiovascular Imaging Inc, Canada) by two senior radiologists independently. The functional parameters of the left ventricle were obtained by analyzing the Cine sequence (short-axis portion) using the LAX module of the software. Cine images of the short and long axes were analyzed by the Strain module to access strain parameters. Semi-automatic delineation of the LV endocardial and epicardial borders was performed in each section at end-diastole, then manually corrected according to the morphological features if necessary. Peak global strain values were obtained by analysis, including peak global circumferential strain (GCS), peak global radial strain (GRS), and peak global longitudinal strain (GLS). The collected CMR delayed enhancement sequences were analyzed using the Tissue Signal Intensity module. The area of delayed enhancement was showed as the high signal area consistent with the distribution of culprit vessels on the LGE image, that was, an area where the signal intensity is greater than 5 standard deviations (SD) of normal myocardial signal [20]. The total infarct size (IS) was described as the percentage of delayed enhancement area volume to total left ventricular volume [21]. On LGE imaging, the persistent and position invariant low signal region within the high signal region throughout the complete cardiac cycle was defined as cardiac microvascular obstruction (CMVO) [22]. Intramyocardial hemorrhage (IMH) presents as the hypointense region within the hyperintense region on T2 sequences, which was attained by T2 module analysis.

Follow up and clinical endpoint

By reviewing the electronic medical records, those patients who completed the evaluation of electrolytes, liver and kidney function, electrocardiogram, and CMR within 3–4 months after PCI were considered to be successfully followed up. The clinical endpoint was the occurrence of ALVR, which was described as an increase ≥ 20% in left ventricular end-diastolic volume (LVEDV) at 3–4 months follow-up CMR compared with baseline measurements [23, 24].

Data collection

Assembled clinical data through electronic medical records, covering demographic information, physical examination data, laboratory parameters, treatment strategies (embracing medication, coronary angiography, and PCI) and correlative indices of CMR.
Demographic information were comprised of sex, age, smoking or drinking history, pre-infarction angina (pre-AP), and Killip class. Physical examination results consisted of body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR). The past medical history contained hypertension, diabetes, coronary artery disease (CAD), and a history of stent implantation. Laboratory parameters included hemoglobin (HGB), white blood cell (WBC) count, platelet (PLT) count, Neutrophil to Lymphocyte Ratio (NLR), total cholesterol (CHOL), low-density lipoprotein cholesterol (LDL-C), lipoprotein a, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), lactate dehydrogenase (LDH), creatine kinase isoenzyme (CKMB), high-sensitivity troponin T (hsTnT), cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), serum creatinine (CREA), serum uric acid (UA), hemoglobin A1c (HbA1c), and high-sensitivity C-reactive protein (hsCRP). All baseline laboratory indicators were first results of laboratory test within 24 h of admission. Treatment strategies contained symptom onset-to-balloon time (SBT), Multivascular disease, left anterior descending branch (LAD), left circumflex branch (LCX), right coronary artery (RCA), non-culprit chronic total occlusion (CTO), door-to-balloon time (D2B), the number of stents, no-reflow, and the use drug of atropine, dopamine, tirofiban, and nitroprusside. CMR parameters included LVEDV, left ventricular end-systolic volume (LVESV), IS, cardiac output (CO), left ventricular ejection fraction (LVEF), CMVO, IMH and strain values GCS, GRS, and GLS.

Statistical analysis

Restricted cubic spline was performed to analyze linear relationships between all candidate continuous variables and ALVR. Categorical data are displayed as the frequency with percentage and checked by chi-square test for comparison. The Continuous indicators that conformed to normal distribution were expressed as mean ± standard deviation (x ± s), using the t-test. Continuous data that did not conform to a normal distribution were expressed as medians (quartile) M (Q1, Q3) and compared by the Mann–Whitney U test. Univariate logistic regression analyses were undertaken to screen the potential risk factors of ALVR in NSTEMI patients who had post-PCI, and the variables with significant differences were further selected into multivariate logistic backward stepwise regression analysis. The nomogram was developed based on the variables whose P-values < 0.05 in multivariate logistic regression analysis, and the performance (discrimination, calibration, and the clinical utility) was assessed. We used bootstrap method for internal validation, with resampling times B = 1000. The concordance index (C-index) is a common measure of discrimination, and the area under the curve (AUC) determined by the receiver operating characteristic curve (ROC) was utilized to represent C-index in this study. The calibration plot and Hosmer–Lemeshow method were performed to observe the consistency between the predicted and the actual probabilities. In addition, Decision-curve analysis was applied to appraise the clinical utility. In all analysis, with P < 0.05 (two-sided test) as the difference was statistically significant. All data were analyzed by R Studio software (version 4.1.3) and Stata software (version 16.0).

Results

Baseline characteristics of training group and validation group

507 NSTEMI patients were involved in our study through screening, then they were assigned to the model for the training group (n = 287) and the external validation group (n = 220). 143 patients were diagnosed with ALVR by re-examining CMR, including 77 (26.80%) in the training team and 66 (30.00%) in the validation team. The differences in baseline characteristics between the two groups were not statistically significant, which showed good comparability (Table 1).
Table 1
Clinical characteristics data in the training and test sets
Characteristics
Training set (n = 287)
Validation set (n = 220)
P value
Age, years
57.0 (50.0–66.0)
57.5 (51.0–65.0)
0.652
Sex
  
0.162
  Male, n (%)
239 (83.28)
193 (87.73)
 
  Female, n (%)
48 (16.72)
27 (12.27)
 
BMI, kg/m2
25.25 (23.14–27.70)
24.98 (22.86–27.68)
0.687
SBP, mmHg
126.0 (115.0–139.0)
127.00 (114.0–139.0)
0.881
DBP, mmHg
80.0 (72.0–90.0)
80.00 (71.0–89.0)
0.484
HR, times/min
80.0 (72.0–89.0)
78.00 (71.0–88.0)
0.385
Smoker, n (%)
  
0.798
  No
135 (47.04)
106 (48.18)
 
  Yes
152 (52.96)
114 (51.82)
 
Drinker, n (%)
  
0.592
  No
153 (53.31)
112 (50.91)
 
  Yes
134 (46.69)
108 (49.09)
 
Hypertension, n (%)
  
0.659
  No
193 (67.25)
152 (69.09)
 
  Yes
94 (32.75)
68 (30.91)
 
Diabetes, n (%)
  
0.276
  No
211 (73.52)
171 (77.73)
 
  Yes
76 (26.48)
49 (22.27)
 
History of CAD, n (%)
  
0.728
  No
214 (74.56)
167 (75.91)
 
  Yes
73 (25.44)
53 (24.09)
 
Laboratory parameters
WBC, × 109/L
10.00 (8.10–11.90)
9.80 (8.00–11.28)
0.341
NLR, %
  
0.346
  < 4.03
107 (37.28)
71 (32.27)
 
  4.03–7.68
99 (34.49)
89 (40.45)
 
  > 7.68
81 (28.22)
60 (27.27)
 
HGB, g/L
148.0 (136.0–158.0)
147.00 (136.0–156.0)
0.444
PLT, × 109/L
213.39 ± 52.67
217.52 ± 55.05
0.436
hs-CRP, mg/dL
4.20 (1.40–11.10)
3.70 (1.40–11.10)
0.907
cTnI, ng/L
14.34 (4.70–32.19)
13.27 (4.54–28.26)
0.594
hsTnT, ng/L
2600.0 (1028.0–1566.0)
2506.0 (989.5–5143.8)
0.718
CKMB, ng/L
  
0.602
  ≦135.00
200 (69.69)
158 (71.82)
 
  > 135.00
87 (30.31)
62 (28.18)
 
NT-proBNP, pg/mL
826.00 (187.00–2100.14)
837.31 (291.49–2120.85)
0.356
CREA, mmol/L
62.0 (54.0–73.0)
62.0 (54.0–73.0)
0.712
UA, umol/L
304.00 (246.00–365.00)
296.00 (242.25–357.50)
0.410
CHOL, mmol/L
4.33 (3.64–5.05)
4.47 (3.80–5.05)
0.300
TG, mmol/L
1.35 (0.91–2.08)
1.42 (1.03–2.06)
0.137
HDL-C, mmol/L
0.99 (0.83–1.21)
1.04 (0.89–1.19)
0.109
LDL-C, mmol/L
2.77 (2.11–3.36)
2.88 (2.23–3.38)
0.123
Lp(a), mg/L
206.00 (129.00–311.00)
207.50 (144.25–325.50)
0.212
LDH, U/L
565.0 (280.0–864.0)
483.0 (257.0–835.0)
0.384
HbA1c, %
6.10 (5.70–6.70)
6.15 (5.70–6.90)
0.183
Angiographic features
SBT, min
240.0 (140.0–390.0)
243.0 (150.0–372.0)
0.764
D2B, min
64.0 (52.0–84.0)
64.5 (52.0–84.0)
0.875
Pre-AP, n (%)
  
0.573
  No
210 (73.17)
156 (70.91)
 
  Yes
77 (26.83)
64 (29.09)
 
Killip class, n (%)
  
0.597
  I
256 (89.2)
201 (91.36)
 
  II
22 (7.67)
15 (6.82)
 
  III
9 (3.14)
4 (1.82)
 
History of stent implant, n (%)
  
0.121
  No
268 (93.38)
197 (89.55)
 
  Yes
19 (6.62)
23 (19.45)
 
Multivascular disease, n (%)
  
0.785
  No
113 (39.37)
84 (38.18)
 
  Yes
174 (60.63)
136 (61.82)
 
LAD, n (%)
  
0.517
  No
143 (49.83)
116 (52.73)
 
  Yes
144 (50.17)
104 (47.27)
 
LCX, n (%)
  
0.463
  No
248 (86.41)
185 (84.09)
 
  Yes
39 (13.59)
35 (15.91)
 
RCA, n (%)
  
0.893
  No
183 (63.76)
139 (63.51)
 
  Yes
104 (36.24)
81 (36.82)
 
non-culprit CTO, n (%)
  
0.852
  No
261 (90.94)
199 (90.45)
 
  Yes
26 (9.06)
21 (9.55)
 
Number of stents, n (%)
  
0.480
  1
250 (87.11)
184 (83.64)
 
  2
35 (12.2)
33 (15)
 
  3
2 (0.7)
3 (1.36)
 
No-reflow, n (%)
  
0.878
  No
204 (71.08)
155 (70.45)
 
  Yes
83 (28.92)
65 (29.55)
 
Intraoperative medication
Tirofiban, n (%)
  
0.653
  No
224 (78.05)
168 (76.36)
 
  Yes
63 (21.95)
52 (23.64)
 
Atropine, n (%)
  
0.630
  No
268 (93.38)
203 (92.27)
 
  Yes
19 (6.62)
17 (7.73)
 
Dopamine, n (%)
  
0.699
  No
269 (93.73)
208 (94.55)
 
  Yes
18 (6.27)
12 (5.45)
 
Nitroprusside, n (%)
  
0.446
  No
183 (63.76)
133 (60.45)
 
  Yes
104 (36.24)
87 (39.55)
 
CMR parameters
LVEF, %
49.43 ± 0.37
50.16 ± 0.60
0.272
IS, %
12.06 (5.50–19.18)
12.32 (4.45–21.04)
0.828
CO, L/min
5.16 (4.20–6.01)
5.04 (4.20–5.66)
0.270
LVEDV, mL
119.49 (100.67–137.37)
117.29 (99.81–137.33)
0.817
LVESV, mL
41.70 (34.03–60.47)
40.69 (31.65–59.90)
0.744
GLS, %
11.80 (− 15.20 to − 8.5)
− 12.00 (− 15.20 to − 9.20)
0.685
GCS, %
− 13.20 (− 15.80 to − 10.20)
− 13.45 (− 16.00 to − 10.10)
0.2705
GRS, %
20.40 (14.70–25.00)
20.45 (13.85–25.20)
0.87
CMVO, n (%)
  
0.651
  No
174 (60.63)
129 (58.64)
 
  Yes
113 (39.37)
91 (41.36)
 
IMH, n (%)
  
0.909
  No
193 (67.25)
149 (67.46)
 
  Yes
94 (32.75)
71 (33.54)
 
AUC, area under the receiver operating characteristics curve; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; HGB, hemoglobin; PLT, platelets; hs-CRP, high-sensitivity C-reactive protein; cTnI, cardiac troponin I; hsTnT, high-sensitivity troponin T; CKMB, creatine kinase isoenzyme-MB; NT-proBNP, N-terminal pro-brain natriuretic peptide; CREA, serum creatinine; UA, serum uric acid; CHOL, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol, Lpa, lipoprotein a; LDH, lactate dehydrogenase; HbA1c, hemoglobin A1c; SBT, symptom onset-to-balloon time; D2B, door-to-balloon time; pre-AP, pre-infarction angina; LAD, left anterior descending; LCX, left circumflex branch; RCA, right coronary artery; non-culprit CTO, non-culprit chronic total occlusion; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; IS, infarct size; CO, cardiac output; GLS, peak global longitudinal strain; GCS, peak global circumferential strain; GRS, peak global radial strain; CMVO, the cardiac microvascular obstruction; IMH, Intramyocardial hemorrhage

Predictors of ALVR after primary PCI

Univariate analysis indicated that males, older age, the increased level of NLR, hsTnT, GLS, IS, the decreased level of LVEF, and the occurrence of Multivascular disease, CMVO and IMH were strongly correlated with the likelihood of ALVR occurring (all P < 0.05) (Table 2). After that, the above variables were brought into multivariable logistic backward stepwise regression analysis to explore the independent prognostic risk factors of NSTEMI patients. Multivariate analysis concluded that age (OR: 1.040; 95% confidence interval (CI): 1.009–1.073), the level of neutrophil to lymphocyte ratio (OR: 4.492; 95% CI: 1.906–10.582), the cardiac microvascular obstruction (OR: 3.416; 95% CI: 1.170–9.970), peak global longitudinal strain (OR: 1.131; 95% CI: 1.026–1.246), infarct size (OR: 1.082; 95% CI: 1.042–1.125) and left ventricular ejection fraction (OR: 0.925; 95% CI: 0.872–0.980) were independent risk factors (Table 3).
Table 2
Univariable logistic regression analysis for 3–4 months ALVR in the training group
Variables
OR
95%CI
P value
Age, years
1.047
(1.020–1.074)
 < 0.001
Sex
0.412
(0.176–0.963)
0.041
BMI, kg/m2
1.011
(0.941–1.086)
0.775
SBP, mmHg
1.012
(0.997–1.027)
0.116
DBP, mmHg
1.009
(0.989–1.030)
0.386
HR, times/min
1.011
(0.990–1.032)
0.317
Smoker, n (%)
1.172
(0.693–1.981)
0.554
Drinker, n (%)
1.157
(0.686–1.952)
0.584
Hypertension, n (%)
1.153
(0.664–1.999)
0.613
Diabetes, n (%)
1.262
(0.707–2.251)
0.431
History of CAD, n (%)
1.247
(0.694–2.242)
0.461
WBC, × 109/L
0.950
(0.867–1.041)
0.273
NLR, %
   
  < 4.03
Ref
Ref
  4.03–7.68
1.482
(0.753–2.914)
0.254
  > 7.68
3.353
(1.725–6.507)
 < 0.001
HB, g/L
0.998
(0.986–1.011)
0.798
PLT, × 109/L
0.997
(0.992–1.002)
0.252
HsCRP, mg/dl
1.004
(0.987–1.021)
0.676
cTnI, ng/L
1.003
(0.987–1.019)
0.720
hsTnT, ng/L
1.00009
(1.000003–1.000176)
0.042
CK-MB, ng/L
1.003
(1.0001–1.0054)
0.039
  ≤ 135
Ref
Ref
  > 135
1.713
(0.989–2.969)
0.055
NT-proBNP, pg/mL
1.00006
(0.9999–1.0002)
0.449
CREA, mmol/L
1.013
(0.995–1.033)
0.160
UA, umol/L
1.0001
(0.997–1.003)
0.917
CHOL, mmol/L
1.076
(0.849–1.362)
0.545
TG, mmol/L
1.013
(0.832–1.232)
0.901
HDL-C, mmol/L
0.917
(0.343–2.450)
0.862
LDL-C, mmol/L
1.150
(0.862–1.533)
0.341
Lp(a), mg/L
0.999
(0.998–1.001)
0.369
LDH, U/L
1.00008
(1.000–1.001)
0.738
HbA1c, %
1.086
(0.896–1.315)
0.400
SBT, min
1.001
(0.999–1.002)
0.298
D2B, min
1.005
(0.997–1.012)
0.239
Pre-AP, n (%)
0.942
(0.520–1.705)
0.843
Killip class, n (%)
1.126
(0.624–2.033)
0.693
History of stent implant, n (%)
1.650
(0.625–4.358)
0.312
Multivascular disease, n (%)
1.761
(1.006–3.081)
0.047
LAD, n (%)
1.183
(0.701–1.996)
0.529
LCX, n (%)
1.438
(0.697–2.965)
0.326
RCA, n (%)
0.933
(0.540–1.610)
0.803
non-culprit CTO, n (%)
2.167
(0.948–4.951)
0.067
Number of stents, n (%)
1.555
(0.794–3.046)
0.198
No-reflow, n (%)
1.368
(0.780–2.400)
0.274
Tirofiban, n (%)
1.119
(0.600–2.084)
0.724
Atropine, n (%)
1.650
(0.625–4.358)
0.312
Dopamine, n (%)
1.052
(0.362–3.056)
0.925
Nitroprusside, n (%)
1.173
(0.685–2.010)
0.561
LVEF, %
0.886
(0.842–0.933)
 < 0.001
IS, %
1.089
(1.055–1.125)
 < 0.001
CO, L/min
0.863
(0.673–1.107)
0.246
LVEDV, mL
1.001
(0.990–1.012)
0.855
LVESV, mL
1.001
(0.988–1.013)
0.913
GLS, %
1.203
(1.109–1.304)
 < 0.001
GCS, %
1.005
(0.935–1.080)
0.896
GRS, %
0.989
(0.947–1.032)
0.610
CMVO, n (%)
2.725
(1.595–4.654)
 < 0.001
IMH, n (%)
2.132
(1.243–3.660)
0.006
CI, confdence interval; ALVR, adverse left ventricular remodeling; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CAD, coronary artery disease; WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; HGB, hemoglobin; PLT, platelets; hs-CRP, high-sensitivity C-reactive protein; cTnI, cardiac troponin I; hsTnT, high-sensitivity troponin T; CKMB, creatine kinase isoenzyme-MB; NT-proBNP, N-terminal pro-brain natriuretic peptide; CREA, serum creatinine; UA, serum uric acid; CHOL, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol, Lpa, lipoprotein a; LDH, lactate dehydrogenase; HbA1c, hemoglobin A1c; SBT, symptom onset-to-balloon time; D2B, door-to-balloon time; pre-AP, pre-infarction angina; LAD, left anterior descending; LCX, left circumflex branch; RCA, right coronary artery; non-culprit CTO, non-culprit chronic total occlusion; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; IS, infarct size; CO, cardiac output; GLS, peak global longitudinal strain; GCS, peak global circumferential strain; GRS, peak global radial strain; CMVO, the cardiac microvascular obstruction; IMH, Intramyocardial hemorrhage
Table 3
Multivariate logistic regression analysis for 3–4 months ALVR in the training group
Variables
OR
95% CI
P value
GLS, %
1.131
(1.026–1.246)
0.013
IS, %
1.083
(1.042–1.125)
 < 0.001
Age, years
1.040
(1.009–1.073)
0.012
NLR, %
   
  < 4.03
Ref
Ref
  4.03–7.68
1.922
(0.843–4.385)
0.120
  > 7.68
4.492
(1.906–10.582)
0.001
CMVO, n (%)
3.416
(1.170–9.970)
0.025
LVEF, %
0.925
(0.872–0.980)
0.009
ALVR, adverse left ventricular remodeling; CMVO, the cardiac microvascular obstruction; GLS, peak global longitudinal strain; IS: infarct size; LVEF, left ventricular ejection fraction; NLR, neutrophil to lymphocyte ratio

Construction of nomogram

A nomogram model was developed based on six factors (age, NLR, CMVO, GLS, IS, and LVEF) correlated with ALVR, according to the univariate and multiple logistic regression analysis (Fig. 2). Regarding the weight of covariates contained in the model, corresponding points were obtained on the scoring line at the top of nomogram through drawing a vertical line. Finally, the individual probability can be determined on the probability line of ALVR in NSTEMI patients with primary PCI through the total points, which can be calculated by adding the points of six factors together.

Validation of the nomogram

The area under the curve (AUC) for the nomogram was 0.805 (95% CI: 0.743–0.860) in the development cohort and 0.867 (95% CI: 0.812–0.914) in the test cohort by the receiver operating characteristic (ROC) curve, which demonstrated an outstanding discrimination (Fig. 3A, B). Furthermore, the Hosmer–Lemeshow test proved that the probabilities of ALVR predicted by the nomogram were consistent with the actual occurrence in the training group, the same findings were also obtained from the validation group (all P > 0.05). The calibration plots indicated a high consistency between the nomogram (Fig. 4A) and external validation cohort (Fig. 4B).

Clinical use

Decision curve analysis (DCA) was used to appraise the applicability and benefit of the model in two datasets. The nomogram showed superior clinical application value when the threshold probability was between 0.05 and 0.80 in training and external validating cohorts (Fig. 5A, B). During this range, the net benefit of the nomogram model (red line) was higher than that of intervention-all-patients (green line) in predicting the risk of ALVR in NSTEMI patients with primary PCI.

Discussion

In this study, we aimed to develop and verify a practicable and straightforward tool to predict the probability for the occurrence of ALVR in NSTEMI patients after reperfusion. Based on logistic regression analysis, age, NLR, IS, EF, GLS and CMVO, six factors were ultimately incorporated into the nomogram model, which consisted of cardiovascular risk factor and imaging data. After that, the nomogram showed excellent performance by verification from three aspects: discrimination, calibration, and clinical utility.
Molecular, cellular and interstitial changes during the period from the acute occlusion of coronary artery to ALVR, eventually leading to heart failure [7]. There is a positive association between the severity of ALVR and the risk of death or hospitalization from heart failure [25, 26]. Consequently, early recognition and clinical intervention of ALVR are of great significance for the prevention of structural destruction or functional deterioration. Liu et al. created a risk prediction model for predicting ALVR in patients with acute anterior STEMI, but their study was incomplete, and even some factors that had been shown to be highly associated with ALVR, such as IS and CMVO, were not considered. Besides, the accuracy of related indexes in their study depending on echocardiography was inferior to CMR [15]. In addition, the performance of their model was uncertain due to the lack of not only a validation set, but also tests of calibration and clinical effectiveness.
It is well known that some factors, such as advanced age, IS, and LVEF, have been recognized as risk factors for poor outcomes after AMI [2527], our results affirmed these conclusions. In epidemiology, the proportion of ALVR after MI in females is higher than in males, and what's more, people with advanced age (female > 65; male > 50) have a high possibility in developing ALVR after MI [2628]. Wu et al. concluded that the probability of ALVR occurrence could increase considerably if the IS ≥ 18.5%. With advancing age, senescent vascular endothelial cells are capable of weakening vascular function by promoting inflammatory response, oxidative stress and thrombosis [29]. After MI, the abnormal wall movement of ischemic and necrotic segments leads to a decrease in ejection volume. But, remarkably, the distal myocardial segment could generate compensatory motion enhancement; thus LVEF may be still maintained in the normal value to a certain extent and time, resulting in its' poor sensitivity for ALVR prediction. Accordingly, we entered strain-related indicators, a series of parameters that accurately reflect local ventricular myocardial function, into this study.
Extensive studies revealed that strain, correlating with IS and infarct mass, demonstrated independently prognostic values in AMI patients [16, 3034]. Interestingly, there has been no consensus on which parameter is more valuable in predicting ALVR. A study including 603 MI patients found that both GCS rate and GLS rate measured by echocardiography were the strongly predictive factors of MACE, while only GCS rate could predict ALVR at 20 months (OR: 1.3, 95% CI: 1.1–1.4) [35]. By comparison, another research containing 232 STEMI patients suggested that strain parameters (only GLS) and CMVO determined by CMR were both significantly associated with the ALVR with a follow-up period of 4 months, in agreement with our findings [36]. The inner myocardium is the most sensitive once myocardial ischemia occurs, because the coronary arteries supply blood from the epicardium toward the endocardium. The myocardial fibers beneath the endocardium are mainly arranged longitudinally in the long-axis direction, while GLS mainly reflects the myocardial strain in the long-axis direction. Those mentioned above may explain that when myocardial ischemia occurs, the earliest corresponding change is in the GLS.
ALVR results from the interaction between persistent and dysregulated inflammation and immunoreaction after acute myocardial ischemia. The increase in N count suggests the severity of inflammatory reaction, and the decrease of L count prompts the intensity of stress response [37]. Therefore, the complex factor NLR is capable of reflecting the inflammatory state well and acts ansignificant role in predicting the prognosis in AMI patients. Actually, reperfusion could cause secondary damage to the myocardium, namely ischemia/reperfusion injury, which is in two major forms: CMVO and IMH, and the presence of IMH indicates a more severe degree of microvascular damage [38, 39]. An animal experiment deduced that with the occurrence of CMVO, the myocardial elasticity in the infarcted area decreased, resulting in the increase of local wall stress [40]. Moreover, the CMVO was allied to an increased size of reduced ventricular wall thickness and minor improvement of ventricular wall thickening [41]. The above mechanisms may joint participation in the potential effect of CMVO on ALVR. Our results further corroborated previous reports. It is worth investigating that there is no uniform conclusion on the relationship between IMH and ALVR. Maria et al. [42] concluded that IMH had a positive relationship with the incidence of major adverse cardiac events (MACE), which was detected by T2* mapping. Nevertheless, in Min Jae Cha et al. study, no remarkable discrepancy in IMH (throughT2 sequences) was observed between patients with and without LV remodeling36. In our research, IMH was excluded from the multiple regression analysis, which may be attributed to the fact that only qualitative measurements were performed and the CMR sequences adopted were inconsistent with other studies.
In this study, we speculated that sex, the level of hsTnT, and Multivascular disease had a strong association with ALVR, not the independent risk factors for it. It is not gender but sex hormones that protect the cardiovascular system through neurohumoral regulation. The composition of sex hormones will change along with growing older, and we didn´t carry out an age-adjusted subgroup analysis for gender. As we know, troponin is the biomarker for detecting myocardial injury, and their concentrations change dynamically with with the duration of myocardial ischemia. Partial reports found that peak hsTnT was the marker of the MACE in MI patients undergoing PCI, but the data we collected was at admission, not at peak concentration.

Limitations

Firstly, the selection bias inherent is inevitable on account of the small sample and retrospective study. Secondly, patients within NSTEMI undergoing primary PCI were not a random sample from the china population. Therefore, it is necessary to perform additional validation of our results with large-scale and multi-center data.

Conclusions

In this predictive study, the clinical calculating tool provided more customized estimators of the likelihood of ALVR in NSTEMI patients by integrating six independent prognostic factors, including Age, NLR, IS, EF, GLS and CMVO. These estimates contribute to prognostic risk stratification early in clinical management.

Acknowledgements

We would like to thank the Affiliated Hospital of Xuzhou Medical University and the Second Affiliated Hospital of Xuzhou Medical University for the relevant information.

Declarations

This study was conducted by the Declaration of Helsinki and was approved by the Medical Research Ethics Committee of the Affiliated Hospital of Xuzhou Medical University.The need for informed consent was waived by the Medical Research Ethics Committee of the Affiliated Hospital of Xuzhou Medical University, because of the retrospective nature of the study.
Not applicable.

Competing interests

The authors declare no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662–75.PubMedCrossRef Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662–75.PubMedCrossRef
2.
Zurück zum Zitat Lawton JS, Tamis-Holland JE, Bangalore S, et al. ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e4–17.PubMed Lawton JS, Tamis-Holland JE, Bangalore S, et al. ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e4–17.PubMed
4.
Zurück zum Zitat Bouisset F, Ruidavets JB, Dallongeville J, et al. Comparison of short- and long-term prognosis between ST-elevation and non-ST-elevation myocardial infarction. J Clin Med. 2021;10(2):180.PubMedCentralCrossRef Bouisset F, Ruidavets JB, Dallongeville J, et al. Comparison of short- and long-term prognosis between ST-elevation and non-ST-elevation myocardial infarction. J Clin Med. 2021;10(2):180.PubMedCentralCrossRef
5.
Zurück zum Zitat Park HW, Yoon CH, Kang SH, et al. Early- and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. Int J Cardiol. 2013;169(4):254–61.PubMedCrossRef Park HW, Yoon CH, Kang SH, et al. Early- and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. Int J Cardiol. 2013;169(4):254–61.PubMedCrossRef
6.
Zurück zum Zitat Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197–210.PubMedCrossRef Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197–210.PubMedCrossRef
7.
Zurück zum Zitat Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail. 2019;7(9):782–94.PubMedCrossRef Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail. 2019;7(9):782–94.PubMedCrossRef
8.
Zurück zum Zitat Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4(1):98–108.PubMedCrossRef Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4(1):98–108.PubMedCrossRef
9.
Zurück zum Zitat Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106(18):2351–7.PubMedCrossRef Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106(18):2351–7.PubMedCrossRef
10.
Zurück zum Zitat Curley D, Lavin Plaza B, Shah AM, Botnar RM. Molecular imaging of cardiac remodelling after myocardial infarction. Basic Res Cardiol. 2018;113(2):10.PubMedPubMedCentralCrossRef Curley D, Lavin Plaza B, Shah AM, Botnar RM. Molecular imaging of cardiac remodelling after myocardial infarction. Basic Res Cardiol. 2018;113(2):10.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Reindl M, Eitel I, Reinstadler SJ. Role of cardiac magnetic resonance to improve risk prediction following acute ST-elevation myocardial infarction. J Clin Med. 2020;9(4):1041.PubMedCentralCrossRef Reindl M, Eitel I, Reinstadler SJ. Role of cardiac magnetic resonance to improve risk prediction following acute ST-elevation myocardial infarction. J Clin Med. 2020;9(4):1041.PubMedCentralCrossRef
12.
Zurück zum Zitat Huttin O, Coiro S, Selton-Suty C, et al. Prediction of left ventricular remodeling after a myocardial infarction: role of myocardial deformation: a systematic review and meta-analysis. PLoS ONE. 2016;11(12): e0168349.PubMedPubMedCentralCrossRef Huttin O, Coiro S, Selton-Suty C, et al. Prediction of left ventricular remodeling after a myocardial infarction: role of myocardial deformation: a systematic review and meta-analysis. PLoS ONE. 2016;11(12): e0168349.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Legallois D, Hodzic A, Alexandre J, et al. Definition of left ventricular remodelling following ST-elevation myocardial infarction: a systematic review of cardiac magnetic resonance studies in the past decade. Heart Fail Rev. 2022;27(1):37–48.PubMedCrossRef Legallois D, Hodzic A, Alexandre J, et al. Definition of left ventricular remodelling following ST-elevation myocardial infarction: a systematic review of cardiac magnetic resonance studies in the past decade. Heart Fail Rev. 2022;27(1):37–48.PubMedCrossRef
14.
Zurück zum Zitat Zhong J, Liu P, Li S, et al. A comparison of three-dimensional speckle tracking echocardiography parameters in predicting left ventricular remodeling. J Healthc Eng. 2020;2020:8847144.PubMedPubMedCentralCrossRef Zhong J, Liu P, Li S, et al. A comparison of three-dimensional speckle tracking echocardiography parameters in predicting left ventricular remodeling. J Healthc Eng. 2020;2020:8847144.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Liu Z, Liu L, Cheng J, Zhang H. Risk prediction model based on biomarkers of remodeling in patients with acute anterior ST-segment elevation myocardial infarction. Med Sci Monit. 2021;27: e927404.PubMedPubMedCentral Liu Z, Liu L, Cheng J, Zhang H. Risk prediction model based on biomarkers of remodeling in patients with acute anterior ST-segment elevation myocardial infarction. Med Sci Monit. 2021;27: e927404.PubMedPubMedCentral
16.
Zurück zum Zitat D’Andrea A, Cocchia R, Caso P, et al. Global longitudinal speckle-tracking strain is predictive of left ventricular remodeling after coronary angioplasty in patients with recent non-ST elevation myocardial infarction. Int J Cardiol. 2011;153(2):185–91.PubMedCrossRef D’Andrea A, Cocchia R, Caso P, et al. Global longitudinal speckle-tracking strain is predictive of left ventricular remodeling after coronary angioplasty in patients with recent non-ST elevation myocardial infarction. Int J Cardiol. 2011;153(2):185–91.PubMedCrossRef
17.
Zurück zum Zitat Kasprzak M, Fabiszak T, Koziński M, Kubica J. Diagnostic performance of selected baseline electrocardiographic parameters for prediction of left ventricular remodeling in patients with ST-segment elevation myocardial infarction. J Clin Med. 2021;10(11):2405.PubMedPubMedCentralCrossRef Kasprzak M, Fabiszak T, Koziński M, Kubica J. Diagnostic performance of selected baseline electrocardiographic parameters for prediction of left ventricular remodeling in patients with ST-segment elevation myocardial infarction. J Clin Med. 2021;10(11):2405.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Makoto OHORI, Gondo T, Hamada R. Nomogram as predictive model in clinical practice. Gan To Kagaku Ryoho. 2009;36(6):901–6. Makoto OHORI, Gondo T, Hamada R. Nomogram as predictive model in clinical practice. Gan To Kagaku Ryoho. 2009;36(6):901–6.
20.
Zurück zum Zitat Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005;7(2):481–5.PubMedCrossRef Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005;7(2):481–5.PubMedCrossRef
21.
Zurück zum Zitat Massalha E, Oren D, Goitein O, et al. Post-ST-segment-elevation myocardial infarction platelet reactivity is associated with the extent of microvascular obstruction and infarct size as determined by cardiac magnetic resonance imaging. J Am Heart Assoc. 2022;11(3): e020973.PubMedPubMedCentralCrossRef Massalha E, Oren D, Goitein O, et al. Post-ST-segment-elevation myocardial infarction platelet reactivity is associated with the extent of microvascular obstruction and infarct size as determined by cardiac magnetic resonance imaging. J Am Heart Assoc. 2022;11(3): e020973.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Abbas A, Matthews GH, Brown IW, Shambrook JS, Peebles CR, Harden SP. Cardiac MR assessment of microvascular obstruction. Br J Radiol. 2015;88(1047):20140470.PubMedPubMedCentralCrossRef Abbas A, Matthews GH, Brown IW, Shambrook JS, Peebles CR, Harden SP. Cardiac MR assessment of microvascular obstruction. Br J Radiol. 2015;88(1047):20140470.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Januzzi JL Jr, Camacho A, Piña IL, et al. Reverse cardiac remodeling and outcome after initiation of sacubitril/valsartan. Circ Heart Fail. 2020;13(6): e006946.PubMedCrossRef Januzzi JL Jr, Camacho A, Piña IL, et al. Reverse cardiac remodeling and outcome after initiation of sacubitril/valsartan. Circ Heart Fail. 2020;13(6): e006946.PubMedCrossRef
24.
Zurück zum Zitat Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569–82.PubMedCrossRef Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569–82.PubMedCrossRef
25.
Zurück zum Zitat Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73–87.PubMedPubMedCentralCrossRef Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73–87.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–34.PubMedCrossRef Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–34.PubMedCrossRef
27.
Zurück zum Zitat Schumacher D, Curaj A, Staudt M, et al. Phosphatidylserine supplementation as a novel strategy for reducing myocardial infarct size and preventing adverse left ventricular remodeling. Int J Mol Sci. 2021;22(9):4401.PubMedPubMedCentralCrossRef Schumacher D, Curaj A, Staudt M, et al. Phosphatidylserine supplementation as a novel strategy for reducing myocardial infarct size and preventing adverse left ventricular remodeling. Int J Mol Sci. 2021;22(9):4401.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Cannata A, Manca P, Nuzzi V, et al. Sex-specific prognostic implications in dilated cardiomyopathy after left ventricular reverse remodeling. J Clin Med. 2020;9(8):2426.PubMedCentralCrossRef Cannata A, Manca P, Nuzzi V, et al. Sex-specific prognostic implications in dilated cardiomyopathy after left ventricular reverse remodeling. J Clin Med. 2020;9(8):2426.PubMedCentralCrossRef
29.
Zurück zum Zitat Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the aging vasculature and role in age-related disease. Circ Res. 2018;123(7):825–48.PubMedPubMedCentralCrossRef Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the aging vasculature and role in age-related disease. Circ Res. 2018;123(7):825–48.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Wang SY, OuYang RZ, Hu LW, et al. Right and left ventricular interactions, strain, and remodeling in repaired pulmonary stenosis patients with preserved right ventricular ejection fraction: a cardiac magnetic resonance study. J Magn Reson Imaging. 2020;52(1):129–38.PubMedCrossRef Wang SY, OuYang RZ, Hu LW, et al. Right and left ventricular interactions, strain, and remodeling in repaired pulmonary stenosis patients with preserved right ventricular ejection fraction: a cardiac magnetic resonance study. J Magn Reson Imaging. 2020;52(1):129–38.PubMedCrossRef
31.
Zurück zum Zitat Reindl M, Tiller C, Holzknecht M, et al. Global longitudinal strain by feature tracking for optimized prediction of adverse remodeling after ST-elevation myocardial infarction. Clin Res Cardiol. 2021;110(1):61–71.PubMedCrossRef Reindl M, Tiller C, Holzknecht M, et al. Global longitudinal strain by feature tracking for optimized prediction of adverse remodeling after ST-elevation myocardial infarction. Clin Res Cardiol. 2021;110(1):61–71.PubMedCrossRef
32.
Zurück zum Zitat Singh A, Voss WB, Lentz RW, Thomas JD, Akhter N. The Diagnostic and prognostic value of echocardiographic strain. JAMA Cardiol. 2019;4(6):580–8.PubMedCrossRef Singh A, Voss WB, Lentz RW, Thomas JD, Akhter N. The Diagnostic and prognostic value of echocardiographic strain. JAMA Cardiol. 2019;4(6):580–8.PubMedCrossRef
33.
Zurück zum Zitat Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100(21):1673–80.PubMedCrossRef Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100(21):1673–80.PubMedCrossRef
34.
Zurück zum Zitat Huntjens PR, Zhang KW, Soyama Y, Karmpalioti M, Lenihan DJ, Gorcsan J 3rd. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging. 2021;14(8):1508–19.PubMedCrossRef Huntjens PR, Zhang KW, Soyama Y, Karmpalioti M, Lenihan DJ, Gorcsan J 3rd. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging. 2021;14(8):1508–19.PubMedCrossRef
35.
Zurück zum Zitat Hung CL, Verma A, Uno H, et al. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol. 2010;56(22):1812–22.PubMedCrossRef Hung CL, Verma A, Uno H, et al. Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol. 2010;56(22):1812–22.PubMedCrossRef
36.
Zurück zum Zitat Cha MJ, Lee JH, Jung HN, Kim Y, Choe YH, Kim SM. Cardiac magnetic resonance-tissue tracking for the early prediction of adverse left ventricular remodeling after ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging. 2019;35(11):2095–102.PubMedCrossRef Cha MJ, Lee JH, Jung HN, Kim Y, Choe YH, Kim SM. Cardiac magnetic resonance-tissue tracking for the early prediction of adverse left ventricular remodeling after ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging. 2019;35(11):2095–102.PubMedCrossRef
37.
Zurück zum Zitat Liu J, Ao W, Zhou J, Luo P, Wang Q, Xiang D. The correlation between PLR-NLR and prognosis in acute myocardial infarction. Am J Transl Res. 2021;13(5):4892–9.PubMedPubMedCentral Liu J, Ao W, Zhou J, Luo P, Wang Q, Xiang D. The correlation between PLR-NLR and prognosis in acute myocardial infarction. Am J Transl Res. 2021;13(5):4892–9.PubMedPubMedCentral
38.
Zurück zum Zitat Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol. 2019;114(6):45.PubMedCrossRef Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol. 2019;114(6):45.PubMedCrossRef
39.
Zurück zum Zitat Liu T, Wang C, Wang L, et al. Development and validation of a clinical and laboratory-based nomogram for predicting coronary microvascular obstruction in NSTEMI patients after primary PCI. Ther Clin Risk Manag. 2022;18:155–69.PubMedPubMedCentralCrossRef Liu T, Wang C, Wang L, et al. Development and validation of a clinical and laboratory-based nomogram for predicting coronary microvascular obstruction in NSTEMI patients after primary PCI. Ther Clin Risk Manag. 2022;18:155–69.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation. 2000;101(23):2734–41.PubMedCrossRef Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation. 2000;101(23):2734–41.PubMedCrossRef
41.
Zurück zum Zitat Zhang L, Mandry D, Chen B, et al. Impact of microvascular obstruction on left ventricular local remodeling after reperfused myocardial infarction. J Magn Reson Imaging. 2018;47(2):499–510.PubMedCrossRef Zhang L, Mandry D, Chen B, et al. Impact of microvascular obstruction on left ventricular local remodeling after reperfused myocardial infarction. J Magn Reson Imaging. 2018;47(2):499–510.PubMedCrossRef
42.
Zurück zum Zitat Ferré-Vallverdú M, Sánchez-Lacuesta E, Plaza-López D, et al. Prognostic value and clinical predictors of intramyocardial hemorrhage measured by CMR T2* sequences in STEMI. Int J Cardiovasc Imaging. 2021;37(5):1735–44.PubMedCrossRef Ferré-Vallverdú M, Sánchez-Lacuesta E, Plaza-López D, et al. Prognostic value and clinical predictors of intramyocardial hemorrhage measured by CMR T2* sequences in STEMI. Int J Cardiovasc Imaging. 2021;37(5):1735–44.PubMedCrossRef
Metadaten
Titel
Development and validation of a predictive model for adverse left ventricular remodeling in NSTEMI patients after primary percutaneous coronary intervention
verfasst von
Lili Wang
Tao Liu
Chaofan Wang
Haochen Xuan
Xianzhi Xu
Jie Yin
Xiaoqun Li
Junhong Chen
Dongye Li
Tongda Xu
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2022
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-022-02831-2

Weitere Artikel der Ausgabe 1/2022

BMC Cardiovascular Disorders 1/2022 Zur Ausgabe

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.